TY - JOUR
T1 - Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants
AU - Li, Wenping
AU - Liang, Yu
AU - Deavers, Michael T.
AU - Kamat, Ashish M.
AU - Matin, Surena F.
AU - Dinney, Colin P.
AU - Czerniak, Bogdan
AU - Guo, Charles C.
N1 - Publisher Copyright:
© American Society for Clinical Pathology.
PY - 2014/12
Y1 - 2014/12
N2 - Objectives: Uroplakin (UP) II and UPIII are highly specific immunohistochemical markers for urothelial differentiation. Here we studied the sensitivity of UPII and UPIII in conventional and variant urothelial carcinomas (UCs). Methods: Immunohistochemical staining for UPII and UPIII was performed on tissue microarray slides, including 105 conventional bladder UCs (BUCs), 90 upper urinary tract UCs (UUTUCs), and 47 micropapillary, 16 plasmacytoid, 22 small cell carcinoma, and 41 sarcomatoid UC variants. Results: UPII expression was significantly higher than UPIII expression in conventional BUC (44% vs 17%, P < .001) and UUTUC (67% vs 46%, P = .045). UPIII expression was significantly higher in UUTUC than in BUC (P < .001). In UC variants, UPII expression was significantly higher than UPIII expression in micropapillary (91% vs 25%, P < .001), plasmacytoid (63% vs 6%, P < .001), and sarcomatoid (29% vs 5%, P = .032) variants. Only rare cases of the small cell carcinoma variant had focal UPII and UPIII expression. Compared with conventional UC, the sarcomatoid variant had significantly lower UPII expression, whereas the micropapillary variant had significantly higher UPII expression (P < .001). Conclusions: UPII demonstrates a significantly higher sensitivity than UPIII in conventional and variant UCs. Thus, UPII is a more valuable marker than UPIII in immunohistochemical analyses for confirming the urothelial origin of carcinomas.
AB - Objectives: Uroplakin (UP) II and UPIII are highly specific immunohistochemical markers for urothelial differentiation. Here we studied the sensitivity of UPII and UPIII in conventional and variant urothelial carcinomas (UCs). Methods: Immunohistochemical staining for UPII and UPIII was performed on tissue microarray slides, including 105 conventional bladder UCs (BUCs), 90 upper urinary tract UCs (UUTUCs), and 47 micropapillary, 16 plasmacytoid, 22 small cell carcinoma, and 41 sarcomatoid UC variants. Results: UPII expression was significantly higher than UPIII expression in conventional BUC (44% vs 17%, P < .001) and UUTUC (67% vs 46%, P = .045). UPIII expression was significantly higher in UUTUC than in BUC (P < .001). In UC variants, UPII expression was significantly higher than UPIII expression in micropapillary (91% vs 25%, P < .001), plasmacytoid (63% vs 6%, P < .001), and sarcomatoid (29% vs 5%, P = .032) variants. Only rare cases of the small cell carcinoma variant had focal UPII and UPIII expression. Compared with conventional UC, the sarcomatoid variant had significantly lower UPII expression, whereas the micropapillary variant had significantly higher UPII expression (P < .001). Conclusions: UPII demonstrates a significantly higher sensitivity than UPIII in conventional and variant UCs. Thus, UPII is a more valuable marker than UPIII in immunohistochemical analyses for confirming the urothelial origin of carcinomas.
KW - Uroplakin II
KW - Uroplakin III
KW - Urothelial carcinoma
KW - Urothelial carcinoma variants
UR - http://www.scopus.com/inward/record.url?scp=84922334633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922334633&partnerID=8YFLogxK
U2 - 10.1309/AJCP1J0JPJBPSUXF
DO - 10.1309/AJCP1J0JPJBPSUXF
M3 - Article
C2 - 25389341
AN - SCOPUS:84922334633
SN - 0002-9173
VL - 142
SP - 864
EP - 871
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 6
ER -